info@seagull-health.com
SeagullHealth
语言:
search
new
Where to Purchase Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR)
501
Article source: Seagull Pharmacy
Dec 17, 2025

Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR) is an important medication for the treatment of type 2 diabetes mellitus. Patients pay close attention to issues such as the legitimacy of its purchase channels, safety of use, and identification of product authenticity.

Where to Purchase Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR)

Overseas Purchase

Patients may choose to consult and purchase the tablets at hospital pharmacies or licensed drugstores in countries/regions where Sitagliptin/Metformin Hydrochloride Extended-Release Tablets have been marketed.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase via Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels, as well as professional consultation and guidance services.

Precautions for Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR)

Strictly Follow the Doctor’s Instructions

Sitagliptin/Metformin Hydrochloride Extended-Release Tablets are prescription-only drugs and must be used under the professional evaluation and guidance of an endocrinologist.

The attending physician will determine the appropriate initial dose based on factors such as whether the patient is already receiving metformin treatment.

Indication Scope

Combined with diet and exercise, Sitagliptin/Metformin Hydrochloride Extended-Release Tablets are indicated to improve glycemic control in adult patients with type 2 diabetes mellitus.

It should be noted that this drug is not indicated for the treatment of type 1 diabetes mellitus, nor has it been studied in patients with a history of pancreatitis.

Identification of Authentic Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR)

Appearance Feature Identification

The extended-release tablets containing 100 mg sitagliptin and 1000 mg metformin hydrochloride are blue, biconvex oval film-coated tablets, engraved with "81" on one side.

The extended-release tablets containing 50 mg sitagliptin and 500 mg metformin hydrochloride are light blue, biconvex oval film-coated tablets, engraved with "78" on one side.

The extended-release tablets containing 50 mg sitagliptin and 1000 mg metformin hydrochloride are light green, biconvex oval film-coated tablets, engraved with "80" on one side.

Anti-Counterfeiting Feature Verification

Packaging integrity check: The packaging of genuine drugs should be intact, with tight seals and no signs of damage or repackaging.

Drug information verification: Check whether the drug approval number, production batch number, validity period and other information on the package box are clear and complete.

Drug source traceability: The authenticity of the drug approval number can be verified through the official website of the national drug regulatory authority to ensure the legality of the drug source.

Batch number and validity period matching: Carefully check whether the batch number and validity period on the inner and outer packaging of the drug are consistent; any discrepancy may indicate a counterfeit product.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
Dosage and Administration of Pemigatinib (Pemazyre) - Recommended Doses
Pemigatinib (Pemazyre) is a targeted therapy for specific genetic abnormalities, mainly indicated for the treatment of cholangiocarcinoma with FGFR2 genetic abnormalities and myeloid/lymphoid neoplasm...
Dosage and Administration of Amlodipine - Recommended Doses
Amlodipine is a long-acting dihydropyridine calcium channel blocker, widely used in the treatment of hypertension and angina pectoris.Dosage and Administration of Amlodipine - Recommended DosesDosage ...
What are the Indications for Amlodipine?
Amlodipine is a long-acting calcium channel blocker that plays an important role in the treatment of cardiovascular diseases. Its orally disintegrating tablet (ODT) formulation further enhances the co...
Where to Purchase Amlodipine
Amlodipine is a long-acting calcium channel blocker widely used in the treatment of hypertension, chronic stable angina pectoris, and vasospastic angina pectoris. As a prescription drug, its standardi...
What are the Indications for Sitagliptin/Metformin Extended-Release Tablets (Janumet XR)?
Sitagliptin/Metformin Extended-Release Tablets (Janumet XR) is a novel fixed-dose combination antihyperglycemic medication. It integrates two hypoglycemic ingredients with distinct mechanisms of actio...
Dosage and Administration, Recommended Dosage of Sitagliptin/Metformin Extended-Release Tablets (Janumet XR)
Sitagliptin/Metformin Extended-Release Tablets (Janumet XR) is a fixed-dose combination oral antihyperglycemic medication. It combines sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with met...
What are the Precautions for Using Sitagliptin/Metformin Extended-Release Tablets (Janumet XR)?
Sitagliptin/Metformin Extended-Release Tablets (Janumet XR) is a combination antihyperglycemic medication that plays an important role in the treatment of type 2 diabetes mellitus. To ensure medicatio...
Adverse Reactions of Sitagliptin/Metformin Extended-Release Tablets (Janumet XR)
Sitagliptin/Metformin Extended-Release Tablets (Janumet XR) is a commonly used fixed-dose combination preparation for type 2 diabetes mellitus. While effectively controlling blood glucose, patients ne...
Related Articles
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
Adverse Reactions of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is an isocitrate dehydrogenase 1 (IDH1) inhibitor, primarily indicated for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and cholangiocarcinoma...
What Are the Precautions for Using Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is a targeted therapy medication primarily indicated for the treatment of patients with malignant hematologic diseases harboring specific gene mutations.What Are the Precautions f...
Dosage and Administration, Recommended Dosage of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is a targeted isocitrate dehydrogenase 1 (IDH1) inhibitor that demonstrates significant value in the treatment of malignant tumors with specific gene mutations.Dosage and Administ...
What Are the Indications for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an oral isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with various malignant tumors harboring specific IDH1 gene mutations. By inhibiting the activity of m...
What Are the Purchase Channels for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an important targeted therapy drug against IDH1 mutations, demonstrating significant efficacy in diseases such as acute myeloid leukemia and cholangiocarcinoma. For patients in...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved